| Abstract |
Colorectal cancer (CRC) is the third most common cancer type worldwide. It
is expected to have more than 2.2 million new cases and 1.1 million deaths
by 2030 in the World. Irinotecan, a topoisomerase I inhibitor, is one of
the widely used drugs in clinic for the treatment of colorectal cancer
(CRC) patients. Despite its efficacy, CRC patients frequently develop
resistance against irinotecan which leads to the treatment failure. The
aim of this thesis is to investigate the underlying mechanisms of
Irinotecan resistance in the LIM 1215 cell line, where acquired resistance
was induced in vitro, as well as to identify potential second-line
therapeutics that can revert the drug resistance. For this purpose,
irinotecan resistant LIM 1215 cell line divided into two groups: one group
continued to be exposed to irinotecan, while the other group was not
exposed to Irinotecan. The transcriptomic changes and secondary drug
sensitivities were analysed for both groups to improve treatment
strategies for CRC patients with irinotecan resistance.
|
|---|
